Esperion Therapeutics, Inc. (ESPR)

Last Closing Price: 3.13 (2026-06-05)

Net Income (Quarterly)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Esperion Therapeutics, Inc. (ESPR) had Net Income of $-25.20M for the most recently reported fiscal quarter, ending 2026-03-31.

Figures for fiscal quarter ending 2026-03-31
Income Statement Financials
$80.10M
Net Income
$-25.20M
$34.57M
$45.53M
$86.69M
$-6.58M
$-18.61M
$-25.20M
$-25.20M
$-25.20M
$-25.20M
$-25.20M
$-25.20M
$-6.58M
$-5.96M
251.35M
251.35M
$-0.10
$-0.10
Balance Sheet Financials
$459.46M
$0.31M
$3.07M
$462.53M
$300.36M
$250.07M
$470.10M
$770.46M
$-307.93M
$-307.99M
$-307.93M
257.40M
Cash Flow Statement Financials
$-27.72M
$-0.19M
$16.22M
$167.85M
$156.16M
$-11.69M
$2.50M
--
--
Fundamental Metrics & Ratios
1.53
--
--
-4.32
-0.81
56.84%
-8.22%
-8.22%
--
-31.45%
-31.45%
$-27.91M
--
--
--
0.17
0.33
0.61
148.70
8.18%
8.18%
-5.45%
43.54%
$-1.20
$-0.11
$-0.11